AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
AtriCure, Inc. (ATRC)
Last atricure, inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atricure.com
Company Research
Source: Business Wire
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium. The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP proc
Show less
Read more
Impact Snapshot
Event Time:
ATRC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRC alerts
High impacting AtriCure, Inc. news events
Weekly update
A roundup of the hottest topics
ATRC
News
- AtriCure, Inc. (NASDAQ: ATRC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug [Yahoo! Finance]Yahoo! Finance
ATRC
Earnings
- 2/15/24 - Beat
ATRC
Sec Filings
- 3/20/24 - Form PRE
- 3/20/24 - Form 4
- 3/18/24 - Form 144
- ATRC's page on the SEC website